BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up. Am J Gastroenterol 2006;101:1048-56. [PMID: 16573777 DOI: 10.1111/j.1572-0241.2006.00524.x] [Cited by in Crossref: 128] [Cited by in F6Publishing: 120] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Nakata S, Kakimoto K, Numa K, Kinoshita N, Kawasaki Y, Tatsumi Y, Tawa H, Koshiba R, Hirata Y, Ota K, Sakiyama N, Kojima Y, Nishikawa H, Inoue T, Takeuchi T, Fukunishi S, Miyazaki T, Nakamura S, Higuchi K. Risk Factors for Nephrotoxicity due to Tacrolimus Therapy for Ulcerative Colitis. Digestion 2022;:1-8. [PMID: 35705006 DOI: 10.1159/000524594] [Reference Citation Analysis]
2 Ferretti F, Cannatelli R, Monico MC, Maconi G, Ardizzone S. An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis. J Clin Med 2022;11:2302. [PMID: 35566428 DOI: 10.3390/jcm11092302] [Reference Citation Analysis]
3 Cai Z, Wang S, Li J. Treatment of Inflammatory Bowel Disease: A Comprehensive Review. Front Med (Lausanne) 2021;8:765474. [PMID: 34988090 DOI: 10.3389/fmed.2021.765474] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
4 Sud S, Sachdeva S, Puri AS. Tacrolimus as rescue therapy for steroid-dependent/steroid-refractory ulcerative colitis: Experience from tertiary referral center in India. Indian J Gastroenterol 2021. [PMID: 34971402 DOI: 10.1007/s12664-021-01185-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Shimizu H, Fujii T, Kinoshita K, Kawamoto A, Hibiya S, Takenaka K, Saito E, Nagahori M, Ohtsuka K, Watanabe M, Okamoto R. Intravenous tacrolimus is a superior induction therapy for acute severe ulcerative colitis compared to oral tacrolimus. BMC Gastroenterol 2021;21:494. [PMID: 34949172 DOI: 10.1186/s12876-021-02043-6] [Reference Citation Analysis]
6 Hoi AY, Morand EF. Treatment Update in Systemic Lupus Erythematous. Rheum Dis Clin North Am 2021;47:513-30. [PMID: 34215377 DOI: 10.1016/j.rdc.2021.04.012] [Reference Citation Analysis]
7 Inflammatory Bowel Disease Group, Chinese Society of Gastroenterology, Chinese Medical Association. Chinese consensus on diagnosis and treatment in inflammatory bowel disease (2018, Beijing). J Dig Dis 2021;22:298-317. [PMID: 33905603 DOI: 10.1111/1751-2980.12994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Iizuka M, Etou T, Shimodaira Y, Hatakeyama T, Sagara S. Cytapheresis re-induces high-rate steroid-free remission in patients with steroid-dependent and steroid-refractory ulcerative colitis. World J Gastroenterol 2021; 27(12): 1194-1212 [PMID: 33828394 DOI: 10.3748/wjg.v27.i12.1194] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Kucharzik T, Dignass AU, Atreya R, Bokemeyer B, Esters P, Herrlinger K, Kannengießer K, Kienle P, Langhorst J, Lügering A, Schreiber S, Stallmach A, Stein J, Sturm A, Teich N, Siegmund B; Collaborators:. Aktualisierte S3-Leitlinie Colitis ulcerosa – Living Guideline. Z Gastroenterol 2020;58:e241-326. [PMID: 33260237 DOI: 10.1055/a-1296-3444] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
10 Nakase H. Optimizing the Use of Current Treatments and Emerging Therapeutic Approaches to Achieve Therapeutic Success in Patients with Inflammatory Bowel Disease. Gut Liver 2020;14:7-19. [PMID: 30919602 DOI: 10.5009/gnl18203] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
11 Gote V, Mandal A, Alshamrani M, Pal D. Self-Assembling Tacrolimus Nanomicelles for Retinal Drug Delivery. Pharmaceutics 2020;12:E1072. [PMID: 33182620 DOI: 10.3390/pharmaceutics12111072] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
12 Wu B, Tong J, Ran Z. Tacrolimus Therapy in Steroid-Refractory Ulcerative Colitis: A Review. Inflamm Bowel Dis. 2020;26:24-32. [PMID: 30980713 DOI: 10.1093/ibd/izz068] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
13 Ito A, Murasugi S, Omori T, Nakamura S, Tokushige K. Relationship between mucosal healing by tacrolimus and relapse of refractory ulcerative colitis: a retrospective study. BMC Gastroenterol 2020;20:203. [PMID: 32590945 DOI: 10.1186/s12876-020-01317-9] [Reference Citation Analysis]
14 Haga K, Shibuya T, Nomura K, Okahara K, Nomura O, Ishikawa D, Sakamoto N, Osada T, Nagahara A. Effectiveness and Nephrotoxicity of Long-Term Tacrolimus Administration in Patients with Ulcerative Colitis. J Clin Med 2020;9:E1771. [PMID: 32517388 DOI: 10.3390/jcm9061771] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Bokemeyer B, Ghiani M, Fuchs A, Deiters B, Hardtstock F, Brandes A, Knop J, Orzechowski HD, Wilke T. Indicators of active disease and steroid dependency in patients with inflammatory bowel diseases not treated with biologics in a German real-world-setting. Int J Colorectal Dis 2020;35:1587-98. [PMID: 32424526 DOI: 10.1007/s00384-020-03588-w] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Rodríguez-Lago I, Castro-Poceiro J, Fernández-Clotet A, Mesonero F, López-Sanromán A, López-García A, Márquez L, Clos-Parals A, Cañete F, Vicuña M, Nantes Ó, Merino O, Matallana V, Gordillo J, Elorza A, Vicente R, Casanova MJ, Ferreiro-Iglesias R, Pérez-Galindo P, Benítez JM, Taxonera C, García MJ, Martín E, Aguirre U, Gisbert JP; Young GETECCU Group. Tacrolimus induces short-term but not long-term clinical response in inflammatory bowel disease. Aliment Pharmacol Ther 2020;51:870-9. [PMID: 32181930 DOI: 10.1111/apt.15687] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
17 Verdon C, Bessissow T, Lakatos PL. Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules. J Clin Med 2019;8:E2169. [PMID: 31817972 DOI: 10.3390/jcm8122169] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
18 Fehily SR, Martin FC, Kamm MA. Simple water-based tacrolimus enemas for refractory proctitis. JGH Open 2020;4:561-4. [PMID: 32782938 DOI: 10.1002/jgh3.12280] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Giron F, Pastó A, Tasciotti E, Abraham BP. Nanotechnology in the Treatment of Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2019;25:1871-80. [DOI: 10.1093/ibd/izz205] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
20 Kim YN, Jung Y. [Renal and Urinary Manifestations of Inflammatory Bowel Disease]. Korean J Gastroenterol 2019;73:260-8. [PMID: 31132832 DOI: 10.4166/kjg.2019.73.5.260] [Reference Citation Analysis]
21 Higashiyama M, Sugita A, Koganei K, Wanatabe K, Yokoyama Y, Uchino M, Nagahori M, Naganuma M, Bamba S, Kato S, Takeuchi K, Omori T, Takagi T, Matsumoto S, Nagasaka M, Sagami S, Kitamura K, Katsurada T, Sugimoto K, Takatsu N, Saruta M, Sakurai T, Watanabe K, Nakamura S, Suzuki Y, Hokari R. Management of elderly ulcerative colitis in Japan. J Gastroenterol 2019;54:571-86. [PMID: 31025187 DOI: 10.1007/s00535-019-01580-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
22 Iida T, Nojima M, Nakase H. Therapeutic Efficacy and Adverse Events of Tacrolimus in Patients with Crohn's Disease: Systematic Review and Meta-Analysis. Dig Dis Sci 2019;64:2945-54. [PMID: 30982208 DOI: 10.1007/s10620-019-05619-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Nishida Y, Hosomi S, Yamagami H, Sugita N, Itani S, Yukawa T, Otani K, Nagami Y, Tanaka F, Taira K, Kamata N, Tanigawa T, Watanabe T, Fujiwara Y. Pretreatment neutrophil-to-lymphocyte ratio predicts clinical relapse of ulcerative colitis after tacrolimus induction. PLoS One. 2019;14:e0213505. [PMID: 30845259 DOI: 10.1371/journal.pone.0213505] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
24 Suzuki T, Mizoshita T, Tanida S, Sugimura N, Katano T, Nishie H, Kataoka H. The efficacy of maintenance therapy after remission induction with tacrolimus in ulcerative colitis with and without previous tumor necrosis factor-α inhibitor. JGH Open 2019;3:217-23. [PMID: 31276039 DOI: 10.1002/jgh3.12140] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Alijotas-Reig J, Esteve-Valverde E, Gil-Aliberas N, Garcia-Gimenez V. Autoimmune/inflammatory syndrome induced by adjuvants-ASIA-related to biomaterials: analysis of 45 cases and comprehensive review of the literature. Immunol Res 2018;66:120-40. [PMID: 29199390 DOI: 10.1007/s12026-017-8980-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
26 Hemperly A, Sandborn WJ, Vande Casteele N. Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2018;24:2527-42. [DOI: 10.1093/ibd/izy189] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
27 Dheer D, Jyoti, Gupta PN, Shankar R. Tacrolimus: An updated review on delivering strategies for multifarious diseases. European Journal of Pharmaceutical Sciences 2018;114:217-27. [DOI: 10.1016/j.ejps.2017.12.017] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
28 Onodera M, Endo K, Kakuta Y, Kuroha M, Kimura T, Hiramoto K, Kanazawa Y, Negoro K, Shiga H, Kinouchi Y, Shimosegawa T. ATP-binding cassette subfamily B member 1 1236C/T polymorphism significantly affects the therapeutic outcome of tacrolimus in patients with refractory ulcerative colitis. J Gastroenterol Hepatol. 2017;32:1562-1569. [PMID: 28135009 DOI: 10.1111/jgh.13753] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
29 Matsumoto S, Kawamura H, Nishikawa T, Sagihara N, Miyatani H, Mashima H. Tacrolimus versus anti-tumor necrosis factor agents for steroid-refractory active ulcerative colitis based on the severity of endoscopic findings: a single-center, open-label cohort study. Clin Exp Gastroenterol 2017;10:249-58. [PMID: 29026326 DOI: 10.2147/CEG.S143224] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
30 Vasudevan A, Gibson PR, Langenberg DRV. Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told? World J Gastroenterol 2017; 23(35): 6385-6402 [PMID: 29085188 DOI: 10.3748/wjg.v23.i35.6385] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 26] [Article Influence: 7.2] [Reference Citation Analysis]
31 Lawrance IC, Baird A, Lightower D, Radford-smith G, Andrews JM, Connor S. Efficacy of Rectal Tacrolimus for Induction Therapy in Patients With Resistant Ulcerative Proctitis. Clinical Gastroenterology and Hepatology 2017;15:1248-55. [DOI: 10.1016/j.cgh.2017.02.027] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 6.4] [Reference Citation Analysis]
32 Truffinet O, Martinez-vinson C, Guerriero E, Hugot J, Viala J. Tacrolimus Exerts Only a Transient Effectiveness in Refractory Pediatric Crohn Disease: A Case Series. Journal of Pediatric Gastroenterology & Nutrition 2017;64:721-5. [DOI: 10.1097/mpg.0000000000001338] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
33 Lasa J, Olivera P. Efficacy of tacrolimus for induction of remission in patients with moderate-to-severe ulcerative colitis: A systematic review and meta-analysis. Arq Gastroenterol. 2017;54:167-172. [PMID: 28327826 DOI: 10.1590/s0004-2803.201700000-15] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
34 Sobrado CW, Sobrado LF. MANAGEMENT OF ACUTE SEVERE ULCERATIVE COLITIS: A CLINICAL UPDATE. Arq Bras Cir Dig 2016;29:201-5. [PMID: 27759787 DOI: 10.1590/0102-6720201600030017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
35 Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Molnár T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F; for the European Crohn’s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. Journal of Crohn's and Colitis 2017;11:769-84. [DOI: 10.1093/ecco-jcc/jjx009] [Cited by in Crossref: 492] [Cited by in F6Publishing: 414] [Article Influence: 98.4] [Reference Citation Analysis]
36 Hosoi K, Arai K, Matsuoka K, Shimizu H, Kamei K, Nakazawa A, Shimizu T, Tang J, Ito S. Prolonged tacrolimus for pediatric gastrointestinal disorder: Double-edged sword? Pediatr Int 2017;59:588-92. [PMID: 27935231 DOI: 10.1111/ped.13211] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
37 Kim EH, Kim DH, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study. Gut Liver 2015;9:601-6. [PMID: 25473080 DOI: 10.5009/gnl14120] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
38 Nuki Y, Esaki M, Asano K, Maehata Y, Umeno J, Moriyama T, Nakamura S, Matsumoto T, Kitazono T. Comparison of the therapeutic efficacy and safety between tacrolimus and infliximab for moderate-to-severe ulcerative colitis: a single center experience. Scand J Gastroenterol. 2016;51:700-705. [PMID: 26818468 DOI: 10.3109/00365521.2016.1138239] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
39 Endo K, Onodera M, Shiga H, Kuroha M, Kimura T, Hiramoto K, Kakuta Y, Kinouchi Y, Shimosegawa T. A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis. Gastroenterol Res Pract. 2016;2016:3162595. [PMID: 26904108 DOI: 10.1155/2016/3162595] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
40 Yamamoto T, Shimoyama T, Umegae S, Matsumoto K. Tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: A retrospective observational study. Aliment Pharmacol Ther. 2016;43:705-716. [PMID: 26762838 DOI: 10.1111/apt.13531] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 5.3] [Reference Citation Analysis]
41 Komaki Y, Komaki F, Ido A, Sakuraba A. Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysis. J Crohns Colitis. 2016;10:484-494. [PMID: 26645641 DOI: 10.1093/ecco-jcc/jjv221] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 6.1] [Reference Citation Analysis]
42 Ikeya K, Hanai H, Sugimoto K, Osawa S, Kawasaki S, Iida T, Maruyama Y, Watanabe F. The Ulcerative Colitis Endoscopic Index of Severity More Accurately Reflects Clinical Outcomes and Long-term Prognosis than the Mayo Endoscopic Score. J Crohns Colitis. 2016;10:286-295. [PMID: 26581895 DOI: 10.1093/ecco-jcc/jjv210] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 9.1] [Reference Citation Analysis]
43 Schmidt KJ, Müller N, Dignass A, Baumgart DC, Lehnert H, Stange EF, Herrlinger KR, Fellermann K, Büning J. Long-term Outcomes in Steroid-refractory Ulcerative Colitis Treated with Tacrolimus Alone or in Combination with Purine Analogues. J Crohns Colitis 2016;10:31-7. [PMID: 26419459 DOI: 10.1093/ecco-jcc/jjv175] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
44 Nakase H, Yoshino T, Matsuura M. Role in calcineurin inhibitors for inflammatory bowel disease in the biologics era: when and how to use. Inflamm Bowel Dis 2014;20:2151-6. [PMID: 25029618 DOI: 10.1097/MIB.0000000000000130] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
45 Matsuoka K, Saito E, Fujii T, Takenaka K, Kimura M, Nagahori M, Ohtsuka K, Watanabe M. Tacrolimus for the Treatment of Ulcerative Colitis. Intest Res. 2015;13:219-226. [PMID: 26130996 DOI: 10.5217/ir.2015.13.3.219] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
46 Nalle SC, Turner JR. Intestinal barrier loss as a critical pathogenic link between inflammatory bowel disease and graft-versus-host disease. Mucosal Immunol 2015;8:720-30. [PMID: 25943273 DOI: 10.1038/mi.2015.40] [Cited by in Crossref: 71] [Cited by in F6Publishing: 66] [Article Influence: 10.1] [Reference Citation Analysis]
47 Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, d'Haens G, d'Hoore A, Mantzanaris G, Novacek G, Öresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, van Assche G. [Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management (Spanish version)]. Rev Gastroenterol Mex 2015;80:32-73. [PMID: 25769217 DOI: 10.1016/j.rgmx.2014.10.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
48 Minami N, Yoshino T, Matsuura M, Koshikawa Y, Yamada S, Toyonaga T, Madian A, Honzawa Y, Nakase H. Tacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational study. BMJ Open Gastroenterol. 2015;2:e000021. [PMID: 26462273 DOI: 10.1136/bmjgast-2014-000021] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
49 Ikeya K, Sugimoto K, Kawasaki S, Iida T, Maruyama Y, Watanabe F, Hanai H. Tacrolimus for remission induction in ulcerative colitis: Mayo endoscopic subscore 0 and 1 predict long-term prognosis. Dig Liver Dis. 2015;47:365-371. [PMID: 25682993 DOI: 10.1016/j.dld.2015.01.149] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
50 Araki T, Kawamura M, Tanaka K, Okita Y, Fujikawa H, Uchida K, Toiyama Y, Inoue Y, Mohri Y, Kusunoki M. FK506-Binding Protein 5 mRNA Levels in Ileal Mucosa Are Associated with Pouchitis in Patients with Ulcerative Colitis. Dig Dis Sci 2015;60:1617-23. [PMID: 25596721 DOI: 10.1007/s10620-015-3528-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
51 Gerich ME, Yoon JL, Targan SR, Ippoliti AF, Vasiliauskas EA. Long-term outcomes of thalidomide in refractory Crohn's disease. Aliment Pharmacol Ther 2015;41:429-37. [PMID: 25511905 DOI: 10.1111/apt.13057] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
52 Kedia S, Ahuja V, Tandon R. Management of acute severe ulcerative colitis. World J Gastrointest Pathophysiol 2014; 5(4): 579-588 [PMID: 25401001 DOI: 10.4291/wjgp.v5.i4.579] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
53 Rush B, Berger L, Rosenfeld G, Bressler B. Tacrolimus Therapy for Ulcerative Colitis-Associated Post-Colectomy Enteritis. ACG Case Rep J. 2014;2:33-35. [PMID: 26157899 DOI: 10.14309/crj.2014.76] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
54 Boschetti G, Nancey S, Moussata D, Stefanescu C, Roblin X, Chauvenet M, Stroeymeyt K, Bouhnik Y, Flourié B. Tacrolimus induction followed by maintenance monotherapy is useful in selected patients with moderate-to-severe ulcerative colitis refractory to prior treatment. Digestive and Liver Disease 2014;46:875-80. [DOI: 10.1016/j.dld.2014.06.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
55 Gomollón F, García-López S, Sicilia B, Gisbert JP, Hinojosa J; en representació del Grupo Espa˜nol de Trabajode Enfermedad de Crohn y Colitis Ulcerosa or Spanish Group for Working on Crohn’sDisease and Ulcerative Colitis (GETECCU). [Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU]. Gastroenterol Hepatol 2013;36:e1-47. [PMID: 24215088 DOI: 10.1016/j.gastrohep.2012.11.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
56 Marchioni Beery R, Kane S. Current approaches to the management of new-onset ulcerative colitis. Clin Exp Gastroenterol. 2014;7:111-132. [PMID: 24872716 DOI: 10.2147/ceg.s35942] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
57 Farkas K, Molnár T, Szepes Z. Ability of different rescue therapies to save the bowel in acute, severe, steroid-refractory ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2014;8:695-702. [DOI: 10.1586/17474124.2014.909726] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
58 Kato K, Ohkusa T, Terao S, Chiba T, Murakami K, Yanaka A, Uehara T, Ishii Y, Soma M, Tajiri H. Adjunct antibiotic combination therapy for steroid-refractory or -dependent ulcerative colitis: an open-label multicentre study. Aliment Pharmacol Ther. 2014;39:949-956. [PMID: 24628398 DOI: 10.1111/apt.12688] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
59 Lawrance IC. What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails? World J Gastroenterol 2014; 20(5): 1248-1258 [PMID: 24574799 DOI: 10.3748/wjg.v20.i5.1248] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
60 Thin LW, Murray K, Lawrance IC. Oral tacrolimus for the treatment of refractory inflammatory bowel disease in the biologic era. Inflamm Bowel Dis. 2013;19:1490-1498. [PMID: 23615528 DOI: 10.1097/mib.0b013e318281f362] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 3.1] [Reference Citation Analysis]
61 Hare NC, Arnott ID, Satsangi J. Therapeutic options in acute severe ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2014;2:357-70. [DOI: 10.1586/17474124.2.3.357] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
62 Hirai F, Takatsu N, Yano Y, Satou Y, Takahashi H, Ishikawa S, Tsurumi K, Hisabe T, Matsui T. Impact of CYP3A5 genetic polymorphisms on the pharmacokinetics and short-term remission in patients with ulcerative colitis treated with tacrolimus: CYP3A5 gene and ulcerative colitis. J Gastroenterol Hepatol 2014;29:60-6. [DOI: 10.1111/jgh.12361] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
63 Naganuma M, Sakuraba A, Hibi T. Ulcerative colitis: prevention of relapse. Expert Rev Gastroenterol Hepatol 2013;7:341-51. [PMID: 23639092 DOI: 10.1586/egh.13.18] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
64 Gerich ME, Pardi DS, Bruining DH, Kammer PP, Becker BD, Tremaine WT. Tacrolimus salvage in anti-tumor necrosis factor antibody treatment-refractory Crohn's disease. Inflamm Bowel Dis 2013;19:1107-11. [PMID: 23518805 DOI: 10.1097/MIB.0b013e318280b154] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
65 Georgakopoulou EA, Scully C. Systemic use of non-biologic agents in orofacial diseases: other immunomodulatory agents. Oral Dis 2015;21:273-82. [PMID: 24028818 DOI: 10.1111/odi.12172] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
66 Aminov RI. Biotic acts of antibiotics. Front Microbiol 2013;4:241. [PMID: 23966991 DOI: 10.3389/fmicb.2013.00241] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
67 Miyoshi J, Matsuoka K, Inoue N, Hisamatsu T, Ichikawa R, Yajima T, Okamoto S, Naganuma M, Sato T, Kanai T, Ogata H, Iwao Y, Hibi T. Mucosal healing with oral tacrolimus is associated with favorable medium- and long-term prognosis in steroid-refractory/dependent ulcerative colitis patients. J Crohns Colitis. 2013;7:e609-e614. [PMID: 23680174 DOI: 10.1016/j.crohns.2013.04.018] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.7] [Reference Citation Analysis]
68 Landy J, Wahed M, Peake ST, Hussein M, Ng SC, Lindsay JO, Hart AL. Oral tacrolimus as maintenance therapy for refractory ulcerative colitis--an analysis of outcomes in two London tertiary centres. J Crohns Colitis. 2013;7:e516-e521. [PMID: 23623737 DOI: 10.1016/j.crohns.2013.03.008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
69 Mizoshita T, Tanida S, Tsukamoto H, Ozeki K, Katano T, Ebi M, Mori Y, Kataoka H, Kamiya T, Joh T. Colon Mucosa Exhibits Loss of Ectopic MUC5AC Expression in Patients with Ulcerative Colitis Treated with Oral Tacrolimus. ISRN Gastroenterol 2013;2013:304894. [PMID: 23691335 DOI: 10.1155/2013/304894] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
70 Landy J, Hart AL. Commentary: short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis. Aliment Pharmacol Ther 2013;37:493. [PMID: 23336680 DOI: 10.1111/apt.12178] [Reference Citation Analysis]
71 Schmidt KJ, Herrlinger KR, Emmrich J, Barthel D, Koc H, Lehnert H, Stange EF, Fellermann K, Büning J. Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients. Aliment Pharmacol Ther. 2013;37:129-136. [PMID: 23121200 DOI: 10.1111/apt.12118] [Cited by in Crossref: 58] [Cited by in F6Publishing: 46] [Article Influence: 5.8] [Reference Citation Analysis]
72 Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, D'Haens G, D'Hoore A, Mantzaris G, Novacek G, Oresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6:991-1030. [PMID: 23040451 DOI: 10.1016/j.crohns.2012.09.002] [Cited by in Crossref: 657] [Cited by in F6Publishing: 574] [Article Influence: 65.7] [Reference Citation Analysis]
73 Hiraoka S, Kato J, Suzuki H, Yamamoto K. Readministration of calcineurin inhibitors for ulcerative colitis. Ann Pharmacother 2012;46:1315-21. [PMID: 23032660 DOI: 10.1345/aph.1R210] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
74 Su L, Ji J, Bian J, Fu Y, Ge Y, Yuan Z. Tacrolimus (FK506) prevents early retinal neovascularization in streptozotocin-induced diabetic mice. Int Immunopharmacol 2012;14:606-12. [PMID: 23032068 DOI: 10.1016/j.intimp.2012.09.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
75 Alijotas-reig J, Garcia-gimenez V, Vilardell-tarrés M. Tacrolimus in the Treatment of Chronic and Refractory Late-Onset Immune-Mediated Adverse Effects Related to Silicone Injections. Dermatologic Surgery 2012;38:38-47. [DOI: 10.1111/j.1524-4725.2011.02221.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
76 McSharry K, Dalzell AM, Leiper K, El-Matary W. Systematic review: the role of tacrolimus in the management of Crohn's disease. Aliment Pharmacol Ther. 2011;34:1282-1294. [PMID: 21999607 DOI: 10.1111/j.1365-2036.2011.04873.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 35] [Article Influence: 4.5] [Reference Citation Analysis]
77 Ogata H, Kato J, Hirai F, Hida N, Matsui T, Matsumoto T, Koyanagi K, Hibi T. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2012;18:803-808. [PMID: 21887732 DOI: 10.1002/ibd.21853] [Cited by in Crossref: 144] [Cited by in F6Publishing: 126] [Article Influence: 13.1] [Reference Citation Analysis]
78 Hindorf U, Andersson P. How are thiopurines used and monitored by Swedish gastroenterologists when treating patients with inflammatory bowel disease? Scandinavian Journal of Gastroenterology 2011;46:1215-21. [DOI: 10.3109/00365521.2011.603162] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
79 Meier J, Sturm A. Current treatment of ulcerative colitis. World J Gastroenterol 2011; 17(27): 3204-3212 [PMID: 21912469 DOI: 10.3748/wjg.v17.i27.3204] [Cited by in F6Publishing: 41] [Reference Citation Analysis]
80 Setoyama H, Ido A, Numata M, Moriuchi A, Yamaji N, Tamai T, Funakawa K, Fujita H, Sakiyama T, Uto H, Oketani M, Tsubouchi H. Repeated enemas with hepatocyte growth factor selectively stimulate epithelial cell proliferation of injured mucosa in rats with experimental colitis. Life Sci 2011;89:269-75. [PMID: 21763320 DOI: 10.1016/j.lfs.2011.06.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
81 Oikonomou KA, Kapsoritakis AN, Stefanidis I, Potamianos SP. Drug-induced nephrotoxicity in inflammatory bowel disease. Nephron Clin Pract. 2011;119:c89-94; discussion c96. [PMID: 21677443 DOI: 10.1159/000326682] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
82 Lawrance IC. Topical agents for idiopathic distal colitis and proctitis. J Gastroenterol Hepatol. 2011;26:36-43. [PMID: 21175791 DOI: 10.1111/j.1440-1746.2010.06497.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
83 Herrlinger KR, Koc H, Winter S, Teml A, Stange EF, Fellermann K, Fritz P, Schwab M, Schaeffeler E. ABCB1 single-nucleotide polymorphisms determine tacrolimus response in patients with ulcerative colitis. Clin Pharmacol Ther. 2011;89:422-428. [PMID: 21289623 DOI: 10.1038/clpt.2010.348] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
84 Terao S, Yamashiro K, Tamura I, Hirano T, Ohkusa T, Kato K. Antibiotic Combination Therapy for Steroid Withdrawal in Steroid-Dependent Ulcerative Colitis. Digestion 2011;83:198-203. [DOI: 10.1159/000321811] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
85 Ng SC, Chan FKL, Sung JJY. Review article: the role of non-biological drugs in refractory inflammatory bowel disease: Review: refractory inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 2011;33:417-27. [DOI: 10.1111/j.1365-2036.2010.04541.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
86 Naganuma M, Fujii T, Watanabe M. The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease. J Gastroenterol. 2011;46:129-137. [PMID: 21132334 DOI: 10.1007/s00535-010-0352-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
87 Yoshino T, Nakase H, Honzawa Y, Matsumura K, Yamamoto S, Takeda Y, Ueno S, Uza N, Masuda S, Inui K, Chiba T. Immunosuppressive effects of tacrolimus on macrophages ameliorate experimental colitis: . Inflammatory Bowel Diseases 2010;16:2022-33. [DOI: 10.1002/ibd.21318] [Cited by in Crossref: 52] [Cited by in F6Publishing: 42] [Article Influence: 4.3] [Reference Citation Analysis]
88 Lawrance IC. Novel topical therapies for distal colitis. World J Gastrointest Pharmacol Ther 2010; 1(5): 87-93 [PMID: 21577301 DOI: 10.4292/wjgpt.v1.i5.87] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
89 Yamamoto S, Nakase H, Matsuura M, Honzawa Y, Masuda S, Inui K, Chiba T. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus. J Gastroenterol Hepatol. 2010;25:886-891. [PMID: 20546441 DOI: 10.1111/j.1440-1746.2009.06206.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
90 Oikonomou K, Kapsoritakis A, Eleftheriadis T, Stefanidis I, Potamianos S. Renal manifestations and complications of inflammatory bowel disease. Inflamm Bowel Dis 2011;17:1034-45. [PMID: 20842645 DOI: 10.1002/ibd.21468] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 4.9] [Reference Citation Analysis]
91 Watson S, Pensabene L, Mitchell P, Bousvaros A. Outcomes and adverse events in children and young adults undergoing tacrolimus therapy for steroid-refractory colitis. Inflamm Bowel Dis. 2011;17:22-29. [PMID: 20722055 DOI: 10.1002/ibd.21418] [Cited by in Crossref: 46] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
92 Ooi CJ, Fock KM, Makharia GK, Goh KL, Ling KL, Hilmi I, Lim WC, Kelvin T, Gibson PR, Gearry RB. The Asia-Pacific consensus on ulcerative colitis. J Gastroenterol Hepatol. 2010;25:453-468. [PMID: 20370724 DOI: 10.1111/j.1440-1746.2010.06241.x] [Cited by in Crossref: 97] [Cited by in F6Publishing: 99] [Article Influence: 8.1] [Reference Citation Analysis]
93 Kaminska B, Swiatek-Machado K. Targeting signaling pathways with small molecules to treat autoimmune disorders. Expert Rev Clin Immunol 2008;4:93-112. [PMID: 20477590 DOI: 10.1586/1744666X.4.1.93] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
94 Rogler G. Gastrointestinal and liver adverse effects of drugs used for treating IBD. Best Pract Res Clin Gastroenterol. 2010;24:157-165. [PMID: 20227029 DOI: 10.1016/j.bpg.2009.10.011] [Cited by in Crossref: 88] [Cited by in F6Publishing: 77] [Article Influence: 7.3] [Reference Citation Analysis]
95 Kornbluth A, Sachar DB;  Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501-23; quiz 524. [PMID: 20068560 DOI: 10.1038/ajg.2009.727] [Cited by in Crossref: 826] [Cited by in F6Publishing: 730] [Article Influence: 68.8] [Reference Citation Analysis]
96 Tung TH. Tacrolimus (FK506): Safety and Applications in Reconstructive Surgery. Hand (N Y) 2010;5:1-8. [PMID: 19363638 DOI: 10.1007/s11552-009-9193-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
97 Schwartz M, Cohen R. Optimizing conventional therapy for inflammatory bowel disease. Curr Gastroenterol Rep 2008;10:585-90. [PMID: 19006615 DOI: 10.1007/s11894-008-0106-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
98 Pieper C, Haag S, Gesenhues S, Holtmann G, Gerken G, Jöckel KH. Guideline adherence and patient satisfaction in the treatment of inflammatory bowel disorders--an evaluation study. BMC Health Serv Res 2009;9:17. [PMID: 19173739 DOI: 10.1186/1472-6963-9-17] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
99 Barrio J, Atienza R, Julián-gómez L, Gil-simón P, García-pajares F, Caro-patón A. Colitis ulcerosa, tacrolimus y curación mucosa. Gastroenterología y Hepatología 2008;31:711-3. [DOI: 10.1016/s0210-5705(08)75825-4] [Reference Citation Analysis]
100 Kannengiesser K, Maaser C, Kucharzik T. Molecular pathogenesis of inflammatory bowel disease: relevance for novel therapies. Per Med 2008;5:609-26. [PMID: 29788621 DOI: 10.2217/17410541.5.6.609] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
101 Swaminath A, Ullman T, Rosen M, Mayer L, Lichtiger S, Abreu MT. Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patients. Aliment Pharmacol Ther. 2009;29:273-278. [PMID: 19006540 DOI: 10.1111/j.1365-2036.2008.03878.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
102 Assche GV, Vermeire S, Rutgeerts P. Treatment of severe steroid refractory ulcerative colitis. World J Gastroenterol 2008; 14(36): 5508-5511 [PMID: 18810767 DOI: 10.3748/wjg.14.5508] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
103 Dumortier J, Lapalus MG, Guillaud O, Poncet G, Gagnieu MC, Partensky C, Scoazec JY. Everolimus for refractory Crohn's disease: a case report. Inflamm Bowel Dis. 2008;14:874-877. [PMID: 18275074 DOI: 10.1002/ibd.20395] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
104 Lawrance IC, Copeland TS. Rectal tacrolimus in the treatment of resistant ulcerative proctitis. Aliment Pharmacol Ther. 2008;28:1214-1220. [PMID: 18761706 DOI: 10.1111/j.1365-2036.2008.03841.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 3.6] [Reference Citation Analysis]
105 Hassan J, van der Net JJ, van Royen-Kerkhof A. Treatment of refractory juvenile dermatomyositis with tacrolimus. Clin Rheumatol 2008;27:1469-71. [PMID: 18716733 DOI: 10.1007/s10067-008-0973-2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
106 Baumgart DC, Macdonald JK, Feagan B. Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane Database Syst Rev. 2008;CD007216. [PMID: 18646177 DOI: 10.1002/14651858.cd007216] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
107 Yamamoto S, Nakase H, Mikami S, Inoue S, Yoshino T, Takeda Y, Kasahara K, Ueno S, Uza N, Kitamura H, Tamaki H, Matsuura M, Inui K, Chiba T. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther. 2008;28:589-597. [PMID: 18549460 DOI: 10.1111/j.1365-2036.2008.03764.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 70] [Article Influence: 5.7] [Reference Citation Analysis]
108 Greenstein RJ, Su L, Juste RA, Brown ST. On the action of cyclosporine A, rapamycin and tacrolimus on M. avium including subspecies paratuberculosis. PLoS One. 2008;3:e2496. [PMID: 18575598 DOI: 10.1371/journal.pone.0002496] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 2.3] [Reference Citation Analysis]
109 Benson A, Barrett T, Sparberg M, Buchman AL. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience. Inflamm Bowel Dis. 2008;14:7-12. [PMID: 17879277 DOI: 10.1002/ibd.20263] [Cited by in Crossref: 70] [Cited by in F6Publishing: 66] [Article Influence: 5.0] [Reference Citation Analysis]
110 Segarra Cantón O, Infante Pina D, Tormo Carnicé R. [Infliximab therapy for inflammatory bowel disease: seven years on]. An Pediatr (Barc) 2007;67:344-51. [PMID: 17949644 DOI: 10.1016/s1695-4033(07)70652-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
111 Juillerat P, Pittet V, Felley C, Mottet C, Froehlich F, Vader JP, Gonvers JJ, Michetti P. Drug safety in Crohn's disease therapy. Digestion 2007;76:161-8. [PMID: 18239408 DOI: 10.1159/000111031] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
112 Bianchi Porro G, Cassinotti A, Ferrara E, Maconi G, Ardizzone S. Review article: the management of steroid dependency in ulcerative colitis. Aliment Pharmacol Ther. 2007;26:779-794. [PMID: 17767462 DOI: 10.1111/j.1365-2036.2007.03334.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
113 Paclik D, Berndt U, Guzy C, Dankof A, Danese S, Holzloehner P, Rosewicz S, Wiedenmann B, Wittig BM, Dignass AU. Galectin-2 induces apoptosis of lamina propria T lymphocytes and ameliorates acute and chronic experimental colitis in mice. J Mol Med (Berl). 2008;86:1395-1406. [PMID: 18064431 DOI: 10.1007/s00109-007-0290-2] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 4.1] [Reference Citation Analysis]
114 Moffatt DC, Bernstein CN. Drug therapy for inflammatory bowel disease in pregnancy and the puerperium. Best Practice & Research Clinical Gastroenterology 2007;21:835-47. [DOI: 10.1016/j.bpg.2007.05.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
115 Chow DK, Leong RW. The use of tacrolimus in the treatment of inflammatory bowel disease. Expert Opinion on Drug Safety 2007;6:479-85. [DOI: 10.1517/14740338.6.5.479] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
116 Schott E, Paul F, Wuerfel JT, Zipp F, Rudolph B, Wiedenmann B, Baumgart DC. Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferonβ 1a. World J Gastroenterol 2007; 13(26): 3638-3640 [PMID: 17659718 DOI: 10.3748/wjg.v13.i26.3638] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
117 Lal S, Hillary Steinhart A. Infliximab for ulcerative colitis following liver transplantation: . European Journal of Gastroenterology & Hepatology 2007;19:277-80. [DOI: 10.1097/meg.0b013e3280116ccc] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
118 Nguyen GC, Harris ML, Dassopoulos T. Insights in immunomodulatory therapies for ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep. 2006;8:499-505. [PMID: 17105689 DOI: 10.1007/s11894-006-0040-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]